Unique ID issued by UMIN | UMIN000003931 |
---|---|
Receipt number | R000004723 |
Scientific Title | Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy |
Date of disclosure of the study information | 2010/07/25 |
Last modified on | 2014/12/13 14:55:50 |
Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy
Pegaptanib for chronic central serous chorioretinopathy
Intravitreal injection of Pegaptanib(Macugen) for chronic central serous chorioretinopathy
Pegaptanib for chronic central serous chorioretinopathy
Japan |
Chronic central serous chorioretinopathy
Ophthalmology |
Others
NO
To evaluate the efficacy of intravitreal injection of Pegaptanib in the treatment of chronic central serous chorioretinopathy.
Efficacy
Confirmatory
Pragmatic
Phase II,III
Proportion of subjects improved in best-corrected distance visual acuity (BCVA) at 24 weeks after initiation of pegaptanib.
1)Mean change in best corrected visual acuity (BCVA) from baseline at 24 weeks.
2)Proportion of subjects who lose less than 15 letters of BCVA from baseline at 24 weeks.
3)Anatomical change by OCT and fluorescein angiography.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
To Evaluate the efficacy of 0.3 mg dose of Pegaptanib in the treatment of chronic central serous retinopathy (CSC).
30 | years-old | <= |
Not applicable |
Male and Female
1)A history of persistent central serous chorioretinopathy present for at least 3 months.
2)Serous neurosensory detachment in the macula, and typical dye leakage pattern in fluorescein angiography.
3)Documented subfoveal fluid by OCT.
4)No signs of choroidal neovascularization.
5)The ability and willingness to provide written informed consent.
1)Prior treatment with laser or PDT.
2)Signs of choroidal neovascularization.
3)Intra ocular surgeries within 3 month prior to screening, in the study eye.
4)Previously vitrectomized eyes.
5)Past history of systemic disease such as:
Diabetic retinopathy.
Mild to severe heart failure (Class III or IV assessed by using the New York Heart Association Functional Classification (NYHA)), unstable angina, acute coronary syndrome, myocardial infarction, or ventricular tachycardia
Clinically significant peripheral vascular disease (amputation or symptoms of claudication)
Renal failure.
Liver failure.
Cerebral infarction within the preceding 12 months.
6)Previously received radiation therapy to the affected eye.
7)Severe allergic reactions to sodium fluorescein dye, indocyanine green dye or Pegaptanib.
8)Pregnancy or potential pregnancy.
9)Unwilling or unable to follow or comply with all study related procedures.
20
1st name | |
Middle name | |
Last name | Yoko Ozawa |
Keio University School of Medicine
Department of Ophthalmology
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
1st name | |
Middle name | |
Last name | Atsuro Uchida |
Keio University School of Medicine
Department of Ophthalmology
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
atsuro@tt.rim.or.jp
Department of Ophthalmology, Keio University School of Medicine
Department of Ophthalmology, Keio University School of Medicine
Self funding
NO
慶應義塾大学病院(東京都)
2010 | Year | 07 | Month | 25 | Day |
Unpublished
Completed
2010 | Year | 04 | Month | 01 | Day |
2010 | Year | 04 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2010 | Year | 07 | Month | 20 | Day |
2014 | Year | 12 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004723